Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results

Cardiff Oncology (NASDAQ:CRDFGet Rating) issued its quarterly earnings results on Friday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02), MarketWatch Earnings reports. Cardiff Oncology had a negative return on equity of 21.05% and a negative net margin of 7,880.50%.

CRDF opened at $1.32 on Friday. Cardiff Oncology has a 12 month low of $1.26 and a 12 month high of $10.24. The company has a fifty day simple moving average of $2.11 and a 200 day simple moving average of $4.07.

Institutional investors have recently modified their holdings of the stock. Morgan Stanley grew its stake in Cardiff Oncology by 1,741.2% in the second quarter. Morgan Stanley now owns 467,461 shares of the company’s stock valued at $3,109,000 after acquiring an additional 442,072 shares during the period. Millennium Management LLC increased its stake in Cardiff Oncology by 228.5% during the 4th quarter. Millennium Management LLC now owns 418,880 shares of the company’s stock worth $2,517,000 after purchasing an additional 291,382 shares in the last quarter. BlackRock Inc. increased its stake in Cardiff Oncology by 6.1% during the 4th quarter. BlackRock Inc. now owns 2,532,248 shares of the company’s stock worth $15,218,000 after purchasing an additional 144,500 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Cardiff Oncology by 49.6% during the 4th quarter. Nuveen Asset Management LLC now owns 352,667 shares of the company’s stock worth $1,877,000 after buying an additional 116,890 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Cardiff Oncology by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 645,084 shares of the company’s stock valued at $3,876,000 after buying an additional 62,927 shares in the last quarter. 56.43% of the stock is currently owned by institutional investors and hedge funds.

CRDF has been the topic of a number of research reports. Maxim Group reduced their target price on shares of Cardiff Oncology from $25.00 to $14.00 in a research report on Monday, January 24th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Cardiff Oncology in a research report on Tuesday, April 12th. Finally, Zacks Investment Research cut Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, March 2nd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.25.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Recommended Stories

Earnings History for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.